FRANKLIN LAKES, N.J.,
March 26, 2019 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced the CE-IVD
certification for the BD FACSDuet™ automated flow cytometry
system. The new fully automated sample preparation instrument
enables clinical laboratories to improve their efficiency by
reducing errors and limiting the manual user interactions required
to run assays on the BD FACSLyric™ clinical flow cytometer.
The BD FACSDuet™ system builds new capabilities into the BD
portfolio of clinical flow cytometry solutions. Collectively, these
solutions may help clinical laboratories improve accuracy and
repeatability of their assays by minimizing manual steps that can
introduce errors.
"The BD FACSDuet system enables us to increase our laboratory's
efficiency and throughput, replacing manual processes with
automated ones that are traceable and that can be automatically
transferred and recorded in our laboratory information system
providing a complete audit trail," said David Bloxham, principal biomedical scientist at
the Hemato-Oncology Diagnostic Service (HODS) at Cambridge University Hospital NHS
Trust.
Physical integration between the BD FACSDuet™ system and the BD
FACSLyric™ clinical flow cytometer allows technicians to load
samples and reagents onto the BD FACSDuet™ system and receive data
once the samples are fully processed from the BD FACSLyric™
clinical flow cytometer. Data integration using the BD FACSLink™
middleware solution, offers bidirectional communication between the
instruments and connectivity with laboratory information systems
(LIS).
"The introduction of the BD FACSDuet system is the natural
continuation of our 40 year history of making reliable flow
cytometry solutions that are more robust and easier to use," said
John Ledek, worldwide president of
Biosciences for BD. "Automation solutions for flow cytometry can go
a long way towards improving accuracy and standardization from
instrument to instrument providing the consistent results that
clinicians depend on to inform patient care."
The BD FACSDuet™ automated flow cytometry system is available as
an in vitro diagnostic (IVD) instrument in Europe and is targeted to be available in
other geographies as soon as regulatory milestones are secured. The
current platform automates the lyse-no-wash process. Existing
systems can be field upgradeable as laboratory needs evolve. For
more information, visit bdbiosciences.com/eu
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of healthcare by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for
healthcare providers. BD and its 65,000 employees have a passion
and commitment to help enhance the safety and efficiency of
clinicians' care delivery process, enable laboratory scientists to
accurately detect disease and advance researchers' capabilities to
develop the next generation of diagnostics and therapeutics. BD has
a presence in virtually every country and partners with
organizations around the world to address some of the most
challenging global health issues. By working in close collaboration
with customers, BD can help enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to healthcare. In
2017, BD welcomed C. R. Bard and its products into the BD family.
For more information on BD, please visit bd.com.
Contacts:
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
gwen.gordon@bd.com
|
monique_dolecki@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-launches-new-automated-flow-cytometry-sample-preparation-instrument-with-ce-ivd-certification-300818084.html
SOURCE BD (Becton, Dickinson and Company)